Op-Ed: Marijuana Rescheduling Delayed, Not Derailed, Says Marijuana Moment

The framing: a slowdown, not a collapse

Marijuana Moment's Monday op-ed argues, in its headline, that the federal effort to move marijuana out of Schedule I is behind schedule but still alive.

The headline reads "The Marijuana Rescheduling Process Has Been Delayed—But Not Derailed." The piece ran October 12, 2026. CannIntel is reporting on the framing and the public record behind it, not adopting the author's full argument, and no author, official or agency is quoted here.

It's an opinion piece, not a Federal Register notice. It doesn't change the legal status of marijuana. What it does capture is a view now common in Washington: the process has stalled at points, but nobody has formally ended it.

That view is testable. A rulemaking is derailed when an agency withdraws it, a court vacates it, or Congress blocks it. A rulemaking is delayed when none of those has happened and the clock keeps running.

Where the procedure actually stands

The federal record shows a two-agency process: a health recommendation first, then a DEA rulemaking that isn't complete until a final rule is published.

The Department of Health and Human Services recommended moving marijuana to Schedule III in August 2023, according to the public record. The DEA followed with a notice of proposed rulemaking published in the Federal Register on May 21, 2024, proposing to place marijuana in Schedule III of the Controlled Substances Act.

Authority for the change sits in 21 U.S.C. 811. That section governs how the Attorney General, acting through the DEA, adds, removes or transfers substances among schedules. It requires findings tied to HHS's scientific and medical evaluation.

A proposal is not a rule. Nothing changes legally until a final rule is published and takes effect. Until then, marijuana stays in Schedule I.

It also drew a request for a formal hearing, which adds procedural steps before any final action. Each step is a place where a timeline can slip without the effort ending. That's the factual core of a "delayed, not derailed" read.

CannIntel's running record of each filing and deadline is on the CannIntel topic hub on DEA marijuana rescheduling.

What operators and investors should price in

Schedule III would remove 280E exposure for licensed operators, but it would leave the federal–state conflict largely intact.

Section 280E of the tax code denies ordinary business deductions to businesses trafficking in Schedule I and II substances. A move to Schedule III would take marijuana outside that provision. For multi-state operators carrying heavy effective tax rates, that is the single largest financial prize in the rescheduling debate.

The caveat is just as plain. Schedule III is still a controlled schedule. It doesn't by itself create a federal pathway for state-licensed dispensaries in California, Ohio or any other adult-use market. Whether and how existing state programs would fit the Controlled Substances Act's registration framework is the harder question, and a final rule would have to answer it or leave it to Congress.

Three variables decide the timeline from here:

• Whether the DEA resolves the hearing process and issues a final rule.
• Whether any court challenge follows a final rule.
• Whether Congress attaches conditions through appropriations or standalone legislation.

A delay isn't free. Operators who budgeted a 280E windfall for a given fiscal year have already absorbed the cost of waiting, and lenders pricing in that relief are carrying the same risk. That math is hard to ignore.

Uncertainty isn't failure, though. Because the proposal is still a live rulemaking, planning around a final rule remains defensible. Planning around a rule on a fixed date isn't.

The next signal to watch is a final rule or a formal withdrawal in the Federal Register. Either one ends the debate over "delayed" versus "derailed." Until one appears, the op-ed's framing is an argument rather than a fact.